Adamas Pharmaceuticals (NASDAQ: ADMS) is down 20.7% at 12:57 p.m. EST after the Food and Drug Administration approved Osmotica Pharmaceutical and Vertical Pharmaceuticals' Osmolex ER, a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback